|
Synonyms: compound Z161 [US20240360154] | GFH-647
Compound class:
Synthetic organic
Comment: GFH647 is a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor. It is one of the compounds claimed in patent US20240360154A1 [1]. GFH647 is intended to treat B cell cancers by targeting wild-type BTK and the ibrutinib resistance mutation BTKC481S.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| References |
|
1. Zhou F, Jiang T, Liu Y, Lin C, Zhang L, Liu Z, Ma K, Xu X, Feng L, Lan X et al.. (2024)
Aroyl substituted tricyclic compound, preparation method therefor and use thereof. Patent number: US20240360154A1. Assignee: Genfleet Therapeutics Shanghai Inc, Zhejiang Genfleet Therapeutics Co Ltd. Priority date: 21/09/2021. Publication date: 31/10/2024. |